

THE GLOBAL MARKET FOR PAIN MANAGEMENT DRUGS AND DEVICES



HLC026E
September 2015

Melissa Elder
Project Analyst

ISBN: 1-62296-156-0



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

| TOPIC | PAGE NO. |
|--|-----------------|
| CHAPTER 1 INTRODUCTION | 2 |
| STUDY GOALS AND OBJECTIVES | 2 |
| REASONS FOR DOING THE STUDY AND INTENDED AUDIENCE | 2 |
| SCOPE AND FORMAT | 2 |
| METHODOLOGY AND SOURCES OF INFORMATION | 3 |
| ANALYST'S CREDENTIALS | 3 |
| RELATED BCC RESEARCH REPORTS | 3 |
| BCC RESEARCH WEBSITE | 4 |
| DISCLAIMER | 4 |
| CHAPTER 2 SUMMARY | 6 |
| OVERVIEW | 6 |
| GENERAL PAIN TERMINOLOGY | 6 |
| MAJOR MARKETS SUMMARY | 7 |
| <i>SUMMARY TABLE MARKET FOR GLOBAL PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES BY REVENUE AT MANUFACTURERS' SALES LEVELS, THROUGH 2020 (\$ MILLIONS)</i> | 8 |
| <i>SUMMARY FIGURE MARKET FOR GLOBAL PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES BY REVENUE AT MANUFACTURERS' SALES LEVELS, 2012-2020 (\$ MILLIONS)</i> | 8 |
| MARKET TRENDS | 9 |
| UNDERTREATMENT ISSUES | 9 |
| PROFESSIONAL PAIN TREATMENT ISSUES | 9 |
| ACCESS TO CARE | 9 |
| FDA APPROVAL REQUIREMENTS FOR PAIN THERAPIES | 10 |
| DRUG DELIVERY SYSTEMS | 10 |
| CHAPTER 3 INDUSTRY OVERVIEW | 12 |
| HISTORY OF PAIN AND PAIN TREATMENT | 12 |
| THE PERCEPTION OF PAIN | 13 |
| Types of Pain | 13 |
| Acute Pain | 14 |
| Chronic Pain | 14 |
| ASSESSMENT OF PAIN | 14 |
| Subjective | 14 |
| Objective | 15 |
| <i>TABLE 1 OBJECTIVE SIGNS OF PAIN</i> | 15 |
| HOW PAIN IS DIAGNOSED | 15 |
| HOW PAIN IS TREATED | 16 |
| <i>FIGURE 1 PAIN-MANAGEMENT TECHNIQUES</i> | 16 |
| DEMOGRAPHICS AND AGING POPULATIONS | 21 |
| Global Demographic Overview | 21 |
| <i>TABLE 2 GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015 (MILLIONS)</i> | 22 |
| <i>FIGURE 2 GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND 2015 (MILLIONS)</i> | 22 |
| The Aging Population | 23 |

| TOPIC | PAGE NO. |
|--|-----------------|
| <i>TABLE 3 ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, THROUGH 2030 (MILLIONS)</i> | 24 |
| <i>FIGURE 3 ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, 2000-2030 (MILLIONS)</i> | 24 |
| Global Life Expectancy | 25 |
| <i>TABLE 4 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980-2015 (YEARS)</i> | 25 |
| <i>FIGURE 4 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980-2015 (YEARS)</i> | 25 |
| THE NEED FOR PAIN MANAGEMENT | 26 |
| Developments in Treating Neuropathic Pain | 26 |
| MIGRAINE HEADACHE PAIN MANAGEMENT | 27 |
| CANCER PAIN MANAGEMENT | 28 |
| Pain Management in Cancer | 29 |
| <i>FIGURE 5 CAUSES OF CANCER PAIN</i> | 29 |
| <i>TABLE 5 CANCER PAIN MEDICATIONS</i> | 30 |
| Developments in Breakthrough Cancer Pain | 31 |
| ORTHOPEDIC PAIN MANAGEMENT | 31 |
| Osteoarthritis | 32 |
| Rheumatoid Arthritis | 32 |
| Ankylosing Spondylitis | 32 |
| Fibromyalgia | 33 |
| Gout | 33 |
| Scleroderma | 33 |
| Lupus | 33 |
| Bursitis and Tendonitis | 33 |
| <i>TABLE 6 ESTIMATED* PREVALENCE/INCIDENCE OF ORTHOPEDIC CONDITIONS BY COUNTRY, AVERAGE FIGURE, 2010-2013 (MILLIONS)</i> | 34 |
| <i>FIGURE 6 ESTIMATED* PREVALENCE/INCIDENCE OF ORTHOPEDIC CONDITIONS BY COUNTRY, AVERAGE FIGURE 2010-2013 (MILLIONS)</i> | 34 |
| HIV/AIDS RELATED PAIN | 35 |
| BURN PAIN | 35 |
| Stages of Burn Healing | 36 |
| Challenges Associated with Burn Pain | 37 |
| Burn Pain Management | 38 |
| <i>FIGURE 7 APPROACH TO BURN PAIN MANAGEMENT</i> | 38 |
| DENTAL PAIN | 39 |
| Treatment for Dental Pain | 39 |
| OBSTETRICS PAIN | 39 |
| <i>TABLE 7 BIRTH RATES AND BIRTHS BY COUNTRY, 2015 (THOUSANDS)</i> | 40 |
| <i>FIGURE 8 BIRTH RATES AND BIRTHS BY COUNTRY, 2015 (THOUSANDS)</i> | 40 |
| SURGICAL PAIN | 41 |
| GENDER AND PAIN | 42 |
| <i>TABLE 8 PEOPLE WHO REPORTED PAIN BY SELECTED CATEGORY AND GENDER IN THE 18+ U.S. POPULATION*, 1997-2010 (THOUSANDS)</i> | 42 |
| OTHER INFLUENCES DETERMINING HOW PAIN IS FELT AMONG INDIVIDUALS | 42 |
| Objective Pain Measurement | 43 |
| PEDIATRIC PAIN | 43 |

| TOPIC | PAGE NO. |
|--|-----------------|
| CHAPTER 4 INDUSTRY TRENDS | 46 |
| OVERVIEW | 46 |
| UNDERTREATMENT ISSUES | 46 |
| PAIN IN OLDER PATIENTS | 46 |
| PAIN IN YOUNGER PATIENTS | 48 |
| TREATMENT OF PAIN AND ISSUES FACING THE PROFESSIONAL SEGMENT | 48 |
| TABLE 9 AVAILABILITY OF EDUCATION IN PAIN MANAGEMENT BY SELECT REGION/COUNTRY | 51 |
| PRESCRIPTION DRUG MONITORING PROGRAMS | 52 |
| TABLE 10 NUMBER OF AGENCIES RESPONSIBLE FOR PDMP IN EACH STATE, BY TYPE | 52 |
| TABLE 11 BENEFITS OF PRESCRIPTION MONITORING PROGRAMS FOR MEDICAL BOARDS | 53 |
| TABLE 12 DRUGS MONITORED BY PDMPS | 53 |
| TABLE 13 STATES WITH ELECTRONIC PRESCRIPTION MONITORING PROGRAMS | 54 |
| FIGURE 9 NUMBER OF STATES WITH ELECTRONIC PRESCRIPTION MONITORING PROGRAMS BY YEAR OF ENACTMENT | 55 |
| TABLE 14 NURSE CONTINUING EDUCATION REQUIREMENTS FOR PAIN MANAGEMENT BY REQUIRING STATE | 57 |
| ACCESS TO CARE | 58 |
| ACCESS TO PALLIATIVE CARE | 58 |
| Assessing the Need for Palliative Care | 59 |
| FIGURE 10 NUMBER OF DEATHS, BY CAUSES OF MORTALITY AND POTENTIAL NEED FOR PALLIATIVE CARE (MILLIONS) | 59 |
| AVAILABILITY OF MEDICATIONS | 61 |
| TABLE 15 WHO ESSENTIAL MEDICINES LIST (ADULTS) FOR PAIN MANAGEMENT | 61 |
| TABLE 16 AVAILABILITY OF INJECTABLE MORPHINE BY REGION | 62 |
| TABLE 17 AVAILABILITY OF ORAL MORPHINE IN HOSPICE-TYPE SETTINGS, BY REGION | 64 |
| International Narcotics Control Board and Obstacles to Availability | 65 |
| FIGURE 11 FACTORS AFFECTING AVAILABILITY OF OPIOIDS FOR MEDICAL NEEDS, 2010 | 65 |
| GOVERNMENT INTERVENTION | 66 |
| Drug Supply | 66 |
| FDA Drug Shortages for Pain Therapies | 66 |
| TABLE 18 FDA ANALGESIA DRUG SHORTAGES BY REPORTING COMPANY, JULY 2015 | 66 |
| Single Convention on Narcotic Drugs | 79 |
| Government Subsidies | 80 |
| PREVENTING OPIOID-INDUCED CONSTIPATION AND REDUCED COMPLIANCE | 80 |
| PUBLIC HEALTHCARE SYSTEMS AROUND THE WORLD | 81 |
| TABLE 19 WORLD HEALTH ORGANIZATION TOP 50 RANKING OF HEALTHCARE SYSTEMS, 2000 | 81 |
| RISING HEALTHCARE COSTS | 83 |
| TABLE 20 HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY COUNTRY, 1980-2015 (%) | 83 |
| FIGURE 12 HEALTH EXPENDITURES AS PERCENT OF GDP BY COUNTRY, 1980-2015 (%) | 83 |
| AVERAGE LENGTH OF STAY | 84 |
| MANAGED CARE PAIN MANAGEMENT ISSUES | 84 |

| TOPIC | PAGE NO. |
|---|-----------------|
| FDA APPROVAL REQUIREMENTS FOR PAIN THERAPIES | 85 |
| FDA APPROVAL REQUIREMENTS FOR PAIN DEVICES | 86 |
| 510(K) EXEMPTIONS | 87 |
| <i>TABLE 21 PARTS 862-892 OF 21 CFR</i> | 87 |
| RISK EVALUATION AND MITIGATION STRATEGY (REMS) | 88 |
| <i>TABLE 22 LIST OF EXTENDED-RELEASE AND LONG-ACTING OPIOID BRAND-NAME PRODUCTS REQUIRED TO HAVE AN OPIOID REMS, MAY 2015</i> | 89 |
| <i>TABLE 23 LIST OF EXTENDED-RELEASE AND LONG-ACTING OPIOID GENERIC PRODUCTS REQUIRED TO HAVE AN OPIOID REMS, MAY 2015</i> | 89 |
| <i>TABLE 24 TRANSMUCOSAL IMMEDIATE-RELEASE FENTANYL PRODUCTS REQUIRED TO HAVE TIRF REMS ACCESS PROGRAM</i> | 91 |
| ACETAMINOPHEN AND FDA CHANGES | 91 |
| <i>TABLE 25 MARKETED ACETAMINOPHEN-CONTAINING PRESCRIPTION PRODUCTS</i> | 92 |
| CODEINE IN COUGH AND COLD MEDICATIONS | 95 |
| NON-ASPIRIN NSAIDS LINKED TO INCREASED RISK OF HEART ATTACK OR STROKE | 95 |
| <i>TABLE 26 NON-ASPIRIN NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)</i> | 96 |
| DRUG DELIVERY SYSTEMS | 96 |
| ORAL AND EXTENDED RELEASE | 97 |
| TOPICAL AND TRANSDERMAL | 97 |
| INTRAVENOUS | 97 |
| INTRANASAL | 97 |
| PATIENT-CONTROLLED ANALGESIA | 98 |
| IONTOPHORESIS | 98 |
| <i>TABLE 27 ADVANTAGES AND DISADVANTAGES OF IONTOPHORETIC DRUG DELIVERY</i> | 98 |
| ELECTROMECHANICAL TRANSPORT | 99 |
| CHAPTER 5 TREATING PAIN | 101 |
| OVERVIEW | 101 |
| PHARMACEUTICAL PAIN MANAGEMENT | 101 |
| PRESCRIPTION PAIN MANAGEMENT PRODUCTS | 101 |
| <i>TABLE 28 RECENT FDA APPLICATIONS/APPROVALS, JANUARY 2010-JULY 2015</i> | 101 |
| Analgesic Drugs | 104 |
| Non-Narcotics | 104 |
| Narcotics | 105 |
| Full and Partial Agonists | 107 |
| Agonist-Antagonists | 107 |
| Nonsteroid Anti-inflammatory Drugs | 109 |
| Antimigraine Drugs | 110 |
| Antidepressant, Anticonvulsants and Other Pain Relieving Drugs | 111 |
| Anesthetics | 111 |
| General Anesthesia | 112 |
| <i>TABLE 29 MOST COMMONLY USED GENERAL ANESTHETIC AGENTS</i> | 112 |
| Local/Regional | 113 |
| Topical | 113 |
| OVER-THE-COUNTER PAIN MANAGEMENT PRODUCTS: OVERVIEW | 114 |
| ANALGESIC DRUGS | 114 |

| TOPIC | PAGE NO. |
|--|-----------------|
| <i>TABLE 30 OTC ACETAMINOPHEN AND ACETAMINOPHEN COMBINATION PRODUCTS</i> | 114 |
| NONSTEROID ANTI-INFLAMMATORY DRUGS | 115 |
| Aspirin Products and Aspirin Combination Products | 116 |
| <i>TABLE 31 OTC ASPIRIN AND ASPIRIN COMBINATION PRODUCTS</i> | 116 |
| Ibuprofen and Ibuprofen Combination Products | 116 |
| <i>TABLE 32 OTC IBUPROFEN AND IBUPROFEN COMBINATION PRODUCTS</i> | 116 |
| Ketoprofen Products | 117 |
| <i>TABLE 33 OTC KETOPROFEN PRODUCTS</i> | 117 |
| Naproxen Compounds | 117 |
| <i>TABLE 34 OTC NONSTEROID ANTI-INFLAMMATORIES</i> | 117 |
| ANTIMIGRAINE DRUGS | 118 |
| <i>TABLE 35 OTC ANTIMIGRAINE PRODUCTS</i> | 118 |
| TOPICAL ANESTHETIC DRUGS | 118 |
| <i>TABLE 36 OTC TOPICAL ANESTHETIC PRODUCTS</i> | 118 |
| PAIN MANAGEMENT DEVICES | 119 |
| STIMULATION THERAPY | 119 |
| Electrotherapy | 119 |
| Neuromuscular Stimulators | 121 |
| Pain TEM | 122 |
| Spine Stimulation | 122 |
| COMBINATION PAIN MANAGEMENT DEVICES | 124 |
| LASER DEVICES | 124 |
| ELECTROMAGNETIC THERAPY DEVICES | 124 |
| INTRATHECAL DEVICES | 125 |
| OTHER PAIN DEVICES AND METHODS | 125 |
| PAIN MANAGEMENT PROCEDURES: STEROIDS, ENDOSCOPY AND FLUOROSCOPY | 126 |
| ALTERNATIVE METHODS OF PAIN MANAGEMENT | 127 |
| PHYSICAL PAIN TREATMENT MODALITIES | 128 |
| Acupuncture/Acupressure | 128 |
| Ice (Cryotherapy) | 130 |
| Joint Mobilization | 130 |
| Manipulation | 130 |
| Massage | 130 |
| Traction | 130 |
| Radiation Therapy | 131 |
| Radio Frequency Neuroablation, Epiduroscopy | 131 |
| Surgery | 132 |
| Whirlpool Bath (Thermotherapy) | 132 |
| PSYCHOLOGICAL PAIN THERAPIES | 132 |
| Biofeedback | 133 |
| Hypnosis | 133 |
| Behavior Modification/Operant Conditioning | 134 |
| Relaxation and Stress Management Training | 134 |
| Imagery | 135 |
| Autogenic Training | 135 |
| Psychosocial Interventions | 135 |
| Distraction and Reframing | 135 |

| TOPIC | PAGE NO. |
|--|-----------------|
| TRACKING THE DEVELOPMENT OF COMPLEMENTARY AND ALTERNATIVE PAIN CONTROL METHODS | 136 |
| <i>TABLE 37 ADULTS 18 YEARS AND OVER IN THE U.S. WHO USED COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) IN THE PAST 12 MONTHS BY THERAPY TYPE, 2002-2015 (THOUSANDS)</i> | 136 |
| <i>FIGURE 13 ADULTS 18 YEARS AND OVER IN THE U.S. WHO USED COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) IN THE PAST 12 MONTHS BY THERAPY TYPE, 2002-2015 (THOUSANDS)</i> | 137 |
| PAIN MANAGEMENT SERVICES AND ORGANIZATIONS | 138 |
| HOME CARE | 138 |
| HOSPICE | 139 |
| <i>FIGURE 14 NUMBER OF HOSPICE PATIENTS SERVED BY YEAR, 2009-2013</i> | 139 |
| <i>TABLE 38 STATISTICS FOR HOSPICE PATIENTS BY CHARACTERISTIC, 2009-2013 (%)</i> | 140 |
| <i>FIGURE 15 PERCENTAGE OF HOSPICE PATIENTS BY GENDER, 2009-2013 (%)</i> | 141 |
| <i>FIGURE 16 PERCENTAGE OF HOSPICE PATIENTS BY AGE GROUP, 2009-2013 (%)</i> | 141 |
| <i>TABLE 39 STATISTICS OF HOSPICE PATIENTS BY PRIMARY DIAGNOSIS (THOUSAND/%)</i> | 142 |
| <i>FIGURE 17 PERCENTAGE OF HOSPICE PATIENTS BY PRIMARY DIAGNOSIS, 2009-2013 (%)</i> | 143 |
| NATIONAL HOSPICE AND PALLIATIVE CARE ORGANIZATION | 144 |
| <i>TABLE 40 NHPCO COMMITTEES</i> | 144 |
| HOSPITALS | 145 |
| <i>TABLE 41 NUMBER OF REGISTERED HOSPITALS BY COUNTRY, 2010</i> | 145 |
| <i>TABLE 42 NUMBER OF REGISTERED U.S. HOSPITALS BY TYPE, 2013</i> | 146 |
| Hospital Departments | 146 |
| Emergency Rooms | 146 |
| Critical Care Units | 147 |
| PAIN CLINICS | 147 |
| <i>TABLE 43 NUMBER OF REGISTERED PAIN CLINICS IN THE U.S. BY STATE, 2015</i> | 148 |
| <i>TABLE 44 NUMBER OF REGISTERED PAIN CLINICS, BY COUNTRY</i> | 149 |
| SKILLED NURSING FACILITIES | 150 |
| CHAPTER 6 PHARMACEUTICAL PAIN MANAGEMENT MARKET SIZE AND ANALYSIS | 152 |
| TOTAL MARKET | 152 |
| PRESCRIPTION PAIN MARKETS BY PRODUCT TYPE | 152 |
| <i>TABLE 45 MARKET FOR GLOBAL PRESCRIPTION PAIN MANAGEMENT PHARMACEUTICALS AT MANUFACTURERS' SALES LEVELS BY CATEGORY, THROUGH 2020 (\$ MILLIONS)</i> | 153 |
| <i>FIGURE 18 MARKET FOR GLOBAL PRESCRIPTION PAIN MANAGEMENT PHARMACEUTICALS AT MANUFACTURERS' SALES LEVELS BY CATEGORY, 2012-2020 (\$ MILLIONS)</i> | 153 |
| NARCOTIC ANALGESICS | 154 |
| <i>TABLE 46 GLOBAL MARKET FOR NARCOTIC ANALGESICS BY REGION, THROUGH 2020 (\$ MILLIONS)</i> | 154 |
| <i>FIGURE 19 GLOBAL MARKET FOR NARCOTIC ANALGESICS BY REGION, 2012-2020 (\$ MILLIONS)</i> | 154 |
| NON-NARCOTIC ANALGESICS | 155 |
| <i>TABLE 47 GLOBAL MARKET FOR NON-NARCOTIC ANALGESICS BY REGION, THROUGH 2020 (\$ MILLIONS)</i> | 156 |

| TOPIC | PAGE NO. |
|---|-----------------|
| <i>FIGURE 20 GLOBAL MARKET FOR NON-NARCOTIC ANALGESICS BY REGION, 2012-2020 (\$ MILLIONS)</i> | 156 |
| ANTIMIGRAINE AGENTS | 156 |
| <i>TABLE 48 GLOBAL MARKET FOR ANTIMIGRAINE AGENTS BY REGION, THROUGH 2020 (\$ MILLIONS)</i> | 157 |
| <i>FIGURE 21 GLOBAL MARKET FOR ANTIMIGRAINE AGENTS BY REGION, 2012-2020 (\$ MILLIONS)</i> | 157 |
| ANESTHETICS | 158 |
| <i>TABLE 49 GLOBAL MARKET FOR ANESTHETICS BY REGION, THROUGH 2020 (\$ MILLIONS)</i> | 158 |
| <i>FIGURE 22 GLOBAL MARKET FOR ANESTHETICS BY REGION, 2012-2020 (\$ MILLIONS)</i> | 158 |
| OTHER DRUG CLASSES | 159 |
| <i>TABLE 50 GLOBAL MARKET FOR OTHER CNS ANALGESICS BY REGION, THROUGH 2020 (\$ MILLIONS)</i> | 159 |
| <i>FIGURE 23 GLOBAL MARKET FOR OTHER CNS ANALGESICS BY REGION, 2012-2020 (\$ MILLIONS)</i> | 160 |
| MARKET PARTICIPANTS | 160 |
| NARCOTIC/NON-NARCOTIC MARKET SHARE | 160 |
| <i>TABLE 51 GLOBAL MARKET FOR PRESCRIPTION NARCOTIC AND NON-NARCOTIC BY MANUFACTURER, 2015 (\$ MILLIONS/%)</i> | 161 |
| <i>FIGURE 24 GLOBAL MARKET FOR PRESCRIPTION NARCOTIC AND NON-NARCOTIC BY MANUFACTURER, 2015 (\$ MILLIONS)</i> | 161 |
| MIGRAINE TREATMENT MARKET SHARE | 161 |
| <i>TABLE 52 GLOBAL MARKET FOR PRESCRIPTION ANTIMIGRAINE DRUG BY MANUFACTURER, 2015 (\$ MILLIONS/%)</i> | 162 |
| <i>FIGURE 25 GLOBAL MARKET FOR PRESCRIPTION ANTIMIGRAINE DRUG BY MANUFACTURER, 2015 (%)</i> | 163 |
| ANESTHETIC MARKET SHARE | 163 |
| <i>TABLE 53 GLOBAL MARKET FOR PRESCRIPTION ANESTHETIC BY MANUFACTURER, 2015 (\$ MILLIONS/%)</i> | 163 |
| <i>FIGURE 26 GLOBAL MARKET FOR PRESCRIPTION ANESTHETIC BY MANUFACTURER, 2015 (%)</i> | 163 |
| FUTURE MARKET ANALYSIS | 164 |
| CHAPTER 7 PAIN MANAGEMENT DEVICE MARKET SIZE AND ANALYSIS | 166 |
| INTRODUCTION | 166 |
| TOTAL PAIN MANAGEMENT DEVICE MARKET | 166 |
| <i>FIGURE 27 GLOBAL PAIN MANAGEMENT DEVICE MARKET AT MANUFACTURERS' SALES LEVELS, 2012-2020 (\$ MILLIONS)</i> | 166 |
| PAIN MARKETS BY PRODUCT TYPE | 167 |
| ELECTROTHERAPY | 167 |
| SPINE STIMULATORS | 167 |
| OTHER PAIN TREATMENT DEVICES | 168 |
| <i>TABLE 54 GLOBAL PAIN MANAGEMENT DEVICE MARKET AT MANUFACTURERS' SALES LEVELS BY PRODUCT TYPE, THROUGH 2020 (\$ MILLIONS)</i> | 168 |
| <i>FIGURE 28 GLOBAL PAIN MANAGEMENT DEVICE MARKET BY PRODUCT TYPE, 2012-2020 (\$ MILLIONS)</i> | 168 |
| <i>TABLE 55 GLOBAL MARKET FOR PAIN MANAGEMENT DEVICES BY REGION, THROUGH 2020 (\$ MILLIONS)</i> | 169 |

| TOPIC | PAGE NO. |
|---|-----------------|
| <i>FIGURE 29 GLOBAL MARKET FOR PAIN MANAGEMENT DEVICES BY REGION, 2012-2020 (\$ MILLIONS)</i> | 169 |
| MARKET PARTICIPANTS | 169 |
| <i>TABLE 56 GLOBAL MARKET FOR NEUROMUSCULAR STIMULATOR/ELECTROTHERAPY DEVICES BY MANUFACTURER, 2015 (\$ MILLIONS/%)</i> | 170 |
| <i>FIGURE 30 GLOBAL MARKET SHARE FOR NEUROMUSCULAR STIMULATOR/ELECTROTHERAPY DEVICES BY MANUFACTURER, 2015 (%)</i> | 170 |
| <i>TABLE 57 GLOBAL MARKET FOR SPINE STIMULATORS BY MANUFACTURER, 2015 (\$ MILLIONS/%)</i> | 171 |
| <i>FIGURE 31 GLOBAL MARKET SHARE FOR SPINE CORD STIMULATORS BY MANUFACTURER, 2015 (%)</i> | 171 |
| FUTURE MARKET ANALYSIS | 171 |
| CHAPTER 8 TOTAL MARKET SUMMARY | 173 |
| TOTAL PAIN MANAGEMENT MARKET | 173 |
| <i>TABLE 58 GLOBAL MARKET FOR PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES BY REVENUE AT MANUFACTURERS' SALES LEVELS, THROUGH 2020 (\$ MILLIONS)</i> | 173 |
| <i>FIGURE 32 GLOBAL MARKET FOR PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES BY REVENUE AT MANUFACTURERS' SALES LEVELS, 2012-2020 (\$ MILLIONS)</i> | 173 |
| MARKET PERCENTAGE BY PRODUCT TYPE | 174 |
| <i>TABLE 59 GLOBAL PAIN MANAGEMENT MARKET BY SEGMENT, 2015 (\$ MILLIONS/%)</i> | 174 |
| <i>FIGURE 33 GLOBAL PAIN MANAGEMENT MARKET SHARE BY SEGMENT, 2015 (%)</i> | 174 |
| MARKETS BY GLOBAL REGION | 175 |
| <i>TABLE 60 GLOBAL MARKET FOR PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES BY REGION, THROUGH 2020 (\$ MILLIONS)</i> | 176 |
| <i>FIGURE 34 GLOBAL MARKET FOR PAIN MANAGEMENT DEVICES BY REGION, 2012-2020 (\$ MILLIONS)</i> | 176 |
| CHAPTER 9 INDUSTRY DEVELOPMENTS | 178 |
| TIMELINE OF RECENT EVENTS AND DEVELOPMENTS | 178 |
| THE PHARMACEUTICAL PIPELINE | 181 |
| <i>TABLE 61 MANUFACTURERS' PAIN-MANAGEMENT DRUG PIPELINES</i> | 181 |
| <i>FIGURE 35 PAIN MANAGEMENT DRUG PIPELINE, BY DEVELOPMENT STATUS</i> | 189 |
| <i>FIGURE 36 PAIN MANAGEMENT DRUG PIPELINE, BY PRIMARY INDICATION</i> | 190 |
| PATENT ANALYSIS | 191 |
| NUMBER OF PATENTS ISSUED FOR PAIN | 192 |
| <i>TABLE 62 NUMBER OF PAIN FOCUS PATENTS ISSUED, BY ABSTRACT DESCRIPTION</i> | 192 |
| <i>TABLE 63 NUMBER OF U.S. PATENTS FOR PAIN-FOCUSED INVENTIONS BY YEAR, JANUARY 2000-JULY 2015</i> | 193 |
| <i>FIGURE 37 NUMBER OF U.S. PATENTS FOR PAIN-FOCUSED INVENTIONS BY YEAR, JANUARY 2000-JULY 2015</i> | 193 |
| DRUG PATENTS FOR SELECTED THERAPIES | 193 |
| <i>TABLE 64 U.S. PATENT EXPIRATION DATES FOR SELECTED PAIN DRUGS</i> | 194 |
| IMPACT OF GENERIC PARTICIPATION | 194 |
| <i>TABLE 65 FIRST-TIME PRESCRIPTION GENERIC PAIN MANAGEMENT AND APPROVALS, APRIL 2005-JULY 2015</i> | 195 |
| PAIN DEVICE CLINICAL TRIALS | 199 |

| TOPIC | PAGE NO. |
|--|-----------------|
| <i>TABLE 66 SELECTED PAIN MANAGEMENT DEVICE TRIALS</i> | 199 |
| <i>FIGURE 38 NUMBER OF PAIN MANAGEMENT DEVICES IN DEVELOPMENT, BY GENERAL STATUS</i> | 200 |
| FUTURE OF PAIN RESEARCH | 200 |
| <i>TABLE 67 PAIN OR PAIN-RELATED CLINICAL TRIALS, BY REGION, 2015</i> | 203 |
| <i>FIGURE 39 PERCENTAGE OF PAIN-FOCUSED CLINICAL TRIALS FOR ALL AGES, BY REGION (%)</i> | 203 |
| PAIN RESEARCH - PEDIATRIC POPULATIONS | 204 |
| <i>FIGURE 40 PERCENTAGE OF PAIN-FOCUSED CLINICAL TRIALS FOR PEDIATRICS, BY REGION (%)</i> | 204 |
| PATIENT OUTCOMES RESEARCH | 205 |
| SELECTED PAIN-RELATED ACQUISITIONS AND ALLIANCES | 205 |
| | |
| CHAPTER 10 COMPANY PROFILES | 208 |
| PHARMACEUTICAL AND DEVICE PAIN MANAGEMENT MANUFACTURERS | 208 |
| ABBVIE INC. | 208 |
| ASTRAZENECA | 208 |
| DEPOMED INC. | 209 |
| DJO GLOBAL INC. | 209 |
| ELI LILLY & CO. | 210 |
| ENDO INTERNATIONAL | 210 |
| GLAXOSMITHKLINE | 211 |
| HISAMITSU PHARMACEUTICAL CO. INC. | 211 |
| JOHNSON & JOHNSON | 212 |
| MEDTRONIC INC. | 212 |
| NOVARTIS INTERNATIONAL AG | 213 |
| PFIZER | 213 |
| PURDUE PHARMACEUTICALS LP | 214 |
| ST. JUDE MEDICAL INC. | 214 |
| | |
| CHAPTER 11 APPENDIX I | 217 |
| PAIN MANAGEMENT PHARMACEUTICAL MANUFACTURERS AND DEVELOPERS | 217 |
| | |
| CHAPTER 12 APPENDIX II | 236 |
| 2015-2016 STATE CONTROLLED SUBSTANCES SCHEDULING AUTHORITIES AND OTHER HELPFUL CONTACT PERSONS | 236 |
| ALABAMA | 236 |
| ALASKA | 236 |
| ARIZONA | 236 |
| ARKANSAS | 237 |
| CALIFORNIA | 237 |
| COLORADO | 237 |
| CONNECTICUT | 238 |
| DELAWARE | 238 |
| DISTRICT OF COLUMBIA | 238 |
| FLORIDA | 238 |
| GEORGIA | 239 |
| HAWAII | 239 |

| TOPIC | PAGE NO. |
|--|-----------------|
| IDAHO | 239 |
| ILLINOIS | 240 |
| INDIANA | 240 |
| IOWA | 241 |
| KANSAS | 241 |
| KENTUCKY | 241 |
| LOUISIANA | 241 |
| MAINE | 242 |
| MARYLAND | 242 |
| MASSACHUSETTS | 242 |
| MICHIGAN | 243 |
| MINNESOTA | 243 |
| MISSISSIPPI | 243 |
| MISSOURI | 244 |
| MONTANA | 244 |
| NEBRASKA | 245 |
| NEVADA | 245 |
| NEW HAMPSHIRE | 245 |
| NEW JERSEY | 246 |
| NEW MEXICO | 246 |
| NEW YORK | 246 |
| NORTH CAROLINA | 247 |
| NORTH DAKOTA | 247 |
| OHIO | 247 |
| OKLAHOMA | 248 |
| OREGON | 248 |
| PENNSYLVANIA | 248 |
| RHODE ISLAND | 249 |
| SOUTH CAROLINA | 249 |
| SOUTH DAKOTA | 249 |
| TENNESSEE | 250 |
| TEXAS | 250 |
| UTAH | 250 |
| VERMONT | 251 |
| VIRGINIA | 251 |
| WASHINGTON | 252 |
| WEST VIRGINIA | 252 |
| WISCONSIN | 252 |
| WYOMING | 253 |
| CHAPTER 13 APPENDIX III | 255 |
| U.S. PAIN SOCIETIES AND ASSOCIATIONS | 255 |
| CHAPTER 14 APPENDIX IV | 257 |
| INTERNATIONAL ASSOCIATIONS AND ORGANIZATIONS | 257 |

LIST OF TABLES

| TABLE HEADING | PAGE NO. |
|---|-----------------|
| SUMMARY TABLE MARKET FOR GLOBAL PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES BY REVENUE AT MANUFACTURERS' SALES LEVELS, THROUGH 2020 (\$ MILLIONS) | 8 |
| TABLE 1 OBJECTIVE SIGNS OF PAIN | 15 |
| TABLE 2 GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015 (MILLIONS) | 22 |
| TABLE 3 ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, THROUGH 2030 (MILLIONS) | 24 |
| TABLE 4 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980-2015 (YEARS) | 25 |
| TABLE 5 CANCER PAIN MEDICATIONS | 30 |
| TABLE 6 ESTIMATED* PREVALENCE/INCIDENCE OF ORTHOPEDIC CONDITIONS BY COUNTRY, AVERAGE FIGURE, 2010-2013 (MILLIONS) | 34 |
| TABLE 7 BIRTH RATES AND BIRTHS BY COUNTRY, 2015 (THOUSANDS) | 40 |
| TABLE 8 PEOPLE WHO REPORTED PAIN BY SELECTED CATEGORY AND GENDER IN THE 18+ U.S. POPULATION*, 1997-2010 (THOUSANDS) | 42 |
| TABLE 9 AVAILABILITY OF EDUCATION IN PAIN MANAGEMENT BY SELECT REGION/COUNTRY | 51 |
| TABLE 10 NUMBER OF AGENCIES RESPONSIBLE FOR PDMP IN EACH STATE, BY TYPE | 52 |
| TABLE 11 BENEFITS OF PRESCRIPTION MONITORING PROGRAMS FOR MEDICAL BOARDS | 53 |
| TABLE 12 DRUGS MONITORED BY PDMPs | 53 |
| TABLE 13 STATES WITH ELECTRONIC PRESCRIPTION MONITORING PROGRAMS | 54 |
| TABLE 14 NURSE CONTINUING EDUCATION REQUIREMENTS FOR PAIN MANAGEMENT BY REQUIRING STATE | 57 |
| TABLE 15 WHO ESSENTIAL MEDICINES LIST (ADULTS) FOR PAIN MANAGEMENT | 61 |
| TABLE 16 AVAILABILITY OF INJECTABLE MORPHINE BY REGION | 62 |
| TABLE 17 AVAILABILITY OF ORAL MORPHINE IN HOSPICE-TYPE SETTINGS, BY REGION | 64 |
| TABLE 18 FDA ANALGESIA DRUG SHORTAGES BY REPORTING COMPANY, JULY 2015 | 66 |
| TABLE 19 WORLD HEALTH ORGANIZATION TOP 50 RANKING OF HEALTHCARE SYSTEMS, 2000 | 81 |
| TABLE 20 HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY COUNTRY, 1980-2015 (%) | 83 |
| TABLE 21 PARTS 862-892 OF 21 CFR | 87 |
| TABLE 22 LIST OF EXTENDED-RELEASE AND LONG-ACTING OPIOID BRAND-NAME PRODUCTS REQUIRED TO HAVE AN OPIOID REMS, MAY 2015 | 89 |
| TABLE 23 LIST OF EXTENDED-RELEASE AND LONG-ACTING OPIOID GENERIC PRODUCTS REQUIRED TO HAVE AN OPIOID REMS, MAY 2015 | 89 |
| TABLE 24 TRANSMUCOSAL IMMEDIATE-RELEASE FENTANYL PRODUCTS REQUIRED TO HAVE TIRF REMS ACCESS PROGRAM | 91 |
| TABLE 25 MARKETED ACETAMINOPHEN-CONTAINING PRESCRIPTION PRODUCTS | 92 |
| TABLE 26 NON-ASPIRIN NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) | 96 |
| TABLE 27 ADVANTAGES AND DISADVANTAGES OF IONTOPHORETIC DRUG DELIVERY | 98 |
| TABLE 28 RECENT FDA APPLICATIONS/APPROVALS, JANUARY 2010-JULY 2015 | 101 |
| TABLE 29 MOST COMMONLY USED GENERAL ANESTHETIC AGENTS | 112 |
| TABLE 30 OTC ACETAMINOPHEN AND ACETAMINOPHEN COMBINATION PRODUCTS | 114 |
| TABLE 31 OTC ASPIRIN AND ASPIRIN COMBINATION PRODUCTS | 116 |
| TABLE 32 OTC IBUPROFEN AND IBUPROFEN COMBINATION PRODUCTS | 116 |
| TABLE 33 OTC KETOPROFEN PRODUCTS | 117 |
| TABLE 34 OTC NONSTEROID ANTI-INFLAMMATORIES | 117 |

| TABLE HEADING | PAGE NO. |
|--|-----------------|
| TABLE 35 OTC ANTIMIGRAINE PRODUCTS | 118 |
| TABLE 36 OTC TOPICAL ANESTHETIC PRODUCTS | 118 |
| TABLE 37 ADULTS 18 YEARS AND OVER IN THE U.S. WHO USED COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) IN THE PAST 12 MONTHS BY THERAPY TYPE, 2002-2015 (THOUSANDS) | 136 |
| TABLE 38 STATISTICS FOR HOSPICE PATIENTS BY CHARACTERISTIC, 2009-2013 (%) | 140 |
| TABLE 39 STATISTICS OF HOSPICE PATIENTS BY PRIMARY DIAGNOSIS (THOUSAND/%) | 142 |
| TABLE 40 NHPCO COMMITTEES | 144 |
| TABLE 41 NUMBER OF REGISTERED HOSPITALS BY COUNTRY, 2010 | 145 |
| TABLE 42 NUMBER OF REGISTERED U.S. HOSPITALS BY TYPE, 2013 | 146 |
| TABLE 43 NUMBER OF REGISTERED PAIN CLINICS IN THE U.S. BY STATE, 2015 | 148 |
| TABLE 44 NUMBER OF REGISTERED PAIN CLINICS, BY COUNTRY | 149 |
| TABLE 45 MARKET FOR GLOBAL PRESCRIPTION PAIN MANAGEMENT PHARMACEUTICALS AT MANUFACTURERS' SALES LEVELS BY CATEGORY, THROUGH 2020 (\$ MILLIONS) | 153 |
| TABLE 46 GLOBAL MARKET FOR NARCOTIC ANALGESICS BY REGION, THROUGH 2020 (\$ MILLIONS) | 154 |
| TABLE 47 GLOBAL MARKET FOR NON-NARCOTIC ANALGESICS BY REGION, THROUGH 2020 (\$ MILLIONS) | 156 |
| TABLE 48 GLOBAL MARKET FOR ANTIMIGRAINE AGENTS BY REGION, THROUGH 2020 (\$ MILLIONS) | 157 |
| TABLE 49 GLOBAL MARKET FOR ANESTHETICS BY REGION, THROUGH 2020 (\$ MILLIONS) | 158 |
| TABLE 50 GLOBAL MARKET FOR OTHER CNS ANALGESICS BY REGION, THROUGH 2020 (\$ MILLIONS) | 159 |
| TABLE 51 GLOBAL MARKET FOR PRESCRIPTION NARCOTIC AND NON-NARCOTIC BY MANUFACTURER, 2015 (\$ MILLIONS/%) | 161 |
| TABLE 52 GLOBAL MARKET FOR PRESCRIPTION ANTIMIGRAINE DRUG BY MANUFACTURER, 2015 (\$ MILLIONS/%) | 162 |
| TABLE 53 GLOBAL MARKET FOR PRESCRIPTION ANESTHETIC BY MANUFACTURER, 2015 (\$ MILLIONS/%) | 163 |
| TABLE 54 GLOBAL PAIN MANAGEMENT DEVICE MARKET AT MANUFACTURERS' SALES LEVELS BY PRODUCT TYPE, THROUGH 2020 (\$ MILLIONS) | 168 |
| TABLE 55 GLOBAL MARKET FOR PAIN MANAGEMENT DEVICES BY REGION, THROUGH 2020 (\$ MILLIONS) | 169 |
| TABLE 56 GLOBAL MARKET FOR NEUROMUSCULAR STIMULATOR/ELECTROTHERAPY DEVICES BY MANUFACTURER, 2015 (\$ MILLIONS/%) | 170 |
| TABLE 57 GLOBAL MARKET FOR SPINE STIMULATORS BY MANUFACTURER, 2015 (\$ MILLIONS/%) | 171 |
| TABLE 58 GLOBAL MARKET FOR PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES BY REVENUE AT MANUFACTURERS' SALES LEVELS, THROUGH 2020 (\$ MILLIONS) | 173 |
| TABLE 59 GLOBAL PAIN MANAGEMENT MARKET BY SEGMENT, 2015 (\$ MILLIONS/%) | 174 |
| TABLE 60 GLOBAL MARKET FOR PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES BY REGION, THROUGH 2020 (\$ MILLIONS) | 176 |
| TABLE 61 MANUFACTURERS' PAIN-MANAGEMENT DRUG PIPELINES | 181 |
| TABLE 62 NUMBER OF PAIN FOCUS PATENTS ISSUED, BY ABSTRACT DESCRIPTION | 192 |
| TABLE 63 NUMBER OF U.S. PATENTS FOR PAIN-FOCUSED INVENTIONS BY YEAR, JANUARY 2000-JULY 2015 | 193 |
| TABLE 64 U.S. PATENT EXPIRATION DATES FOR SELECTED PAIN DRUGS | 194 |

| TABLE HEADING | PAGE NO. |
|--|-----------------|
| TABLE 65 FIRST-TIME PRESCRIPTION GENERIC PAIN MANAGEMENT AND APPROVALS, APRIL 2005-JULY 2015 | 195 |
| TABLE 66 SELECTED PAIN MANAGEMENT DEVICE TRIALS | 199 |
| TABLE 67 PAIN OR PAIN-RELATED CLINICAL TRIALS, BY REGION, 2015 | 203 |

LIST OF FIGURES

| FIGURE TITLE | PAGE NO. |
|---|-----------------|
| SUMMARY FIGURE MARKET FOR GLOBAL PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES BY REVENUE AT MANUFACTURERS' SALES LEVELS, 2012-2020 (\$ MILLIONS) | 8 |
| FIGURE 1 PAIN-MANAGEMENT TECHNIQUES | 16 |
| FIGURE 2 GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND 2015 (MILLIONS) | 22 |
| FIGURE 3 ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, 2000-2030 (MILLIONS) | 24 |
| FIGURE 4 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980-2015 (YEARS) | 25 |
| FIGURE 5 CAUSES OF CANCER PAIN | 29 |
| FIGURE 6 ESTIMATED* PREVALENCE/INCIDENCE OF ORTHOPEDIC CONDITIONS BY COUNTRY, AVERAGE FIGURE 2010-2013 (MILLIONS) | 34 |
| FIGURE 7 APPROACH TO BURN PAIN MANAGEMENT | 38 |
| FIGURE 8 BIRTH RATES AND BIRTHS BY COUNTRY, 2015 (THOUSANDS) | 40 |
| FIGURE 9 NUMBER OF STATES WITH ELECTRONIC PRESCRIPTION MONITORING PROGRAMS BY YEAR OF ENACTMENT | 55 |
| FIGURE 10 NUMBER OF DEATHS, BY CAUSES OF MORTALITY AND POTENTIAL NEED FOR PALLIATIVE CARE (MILLIONS) | 59 |
| FIGURE 11 FACTORS AFFECTING AVAILABILITY OF OPIOIDS FOR MEDICAL NEEDS, 2010 | 65 |
| FIGURE 12 HEALTH EXPENDITURES AS PERCENT OF GDP BY COUNTRY, 1980-2015 (%) | 83 |
| FIGURE 13 ADULTS 18 YEARS AND OVER IN THE U.S. WHO USED COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) IN THE PAST 12 MONTHS BY THERAPY TYPE, 2002-2015 (THOUSANDS) | 137 |
| FIGURE 14 NUMBER OF HOSPICE PATIENTS SERVED BY YEAR, 2009-2013 | 139 |
| FIGURE 15 PERCENTAGE OF HOSPICE PATIENTS BY GENDER, 2009-2013 (%) | 141 |
| FIGURE 16 PERCENTAGE OF HOSPICE PATIENTS BY AGE GROUP, 2009-2013 (%) | 141 |
| FIGURE 17 PERCENTAGE OF HOSPICE PATIENTS BY PRIMARY DIAGNOSIS, 2009-2013 (%) | 143 |
| FIGURE 18 MARKET FOR GLOBAL PRESCRIPTION PAIN MANAGEMENT PHARMACEUTICALS AT MANUFACTURERS' SALES LEVELS BY CATEGORY, 2012-2020 (\$ MILLIONS) | 153 |
| FIGURE 19 GLOBAL MARKET FOR NARCOTIC ANALGESICS BY REGION, 2012-2020 (\$ MILLIONS) | 154 |
| FIGURE 20 GLOBAL MARKET FOR NON-NARCOTIC ANALGESICS BY REGION, 2012-2020 (\$ MILLIONS) | 156 |
| FIGURE 21 GLOBAL MARKET FOR ANTIMIGRAINE AGENTS BY REGION, 2012-2020 (\$ MILLIONS) | 157 |
| FIGURE 22 GLOBAL MARKET FOR ANESTHETICS BY REGION, 2012-2020 (\$ MILLIONS) | 158 |
| FIGURE 23 GLOBAL MARKET FOR OTHER CNS ANALGESICS BY REGION, 2012-2020 (\$ MILLIONS) | 160 |
| FIGURE 24 GLOBAL MARKET FOR PRESCRIPTION NARCOTIC AND NON-NARCOTIC BY MANUFACTURER, 2015 (\$ MILLIONS) | 161 |
| FIGURE 25 GLOBAL MARKET FOR PRESCRIPTION ANTIMIGRAINE DRUG BY MANUFACTURER, 2015 (%) | 163 |
| FIGURE 26 GLOBAL MARKET FOR PRESCRIPTION ANESTHETIC BY MANUFACTURER, 2015 (%) | 163 |
| FIGURE 27 GLOBAL PAIN MANAGEMENT DEVICE MARKET AT MANUFACTURERS' SALES LEVELS, 2012-2020 (\$ MILLIONS) | 166 |

| FIGURE TITLE | PAGE NO. |
|--|-----------------|
| FIGURE 28 GLOBAL PAIN MANAGEMENT DEVICE MARKET BY PRODUCT TYPE, 2012-2020 (\$ MILLIONS) | 168 |
| FIGURE 29 GLOBAL MARKET FOR PAIN MANAGEMENT DEVICES BY REGION, 2012-2020 (\$ MILLIONS) | 169 |
| FIGURE 30 GLOBAL MARKET SHARE FOR NEUROMUSCULAR STIMULATOR/ELECTROTHERAPY DEVICES BY MANUFACTURER, 2015 (%) | 170 |
| FIGURE 31 GLOBAL MARKET SHARE FOR SPINE CORD STIMULATORS BY MANUFACTURER, 2015 (%) | 171 |
| FIGURE 32 GLOBAL MARKET FOR PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES BY REVENUE AT MANUFACTURERS' SALES LEVELS, 2012-2020 (\$ MILLIONS) | 173 |
| FIGURE 33 GLOBAL PAIN MANAGEMENT MARKET SHARE BY SEGMENT, 2015 (%) | 174 |
| FIGURE 34 GLOBAL MARKET FOR PAIN MANAGEMENT DEVICES BY REGION, 2012-2020 (\$ MILLIONS) | 176 |
| FIGURE 35 PAIN MANAGEMENT DRUG PIPELINE, BY DEVELOPMENT STATUS | 189 |
| FIGURE 36 PAIN MANAGEMENT DRUG PIPELINE, BY PRIMARY INDICATION | 190 |
| FIGURE 37 NUMBER OF U.S. PATENTS FOR PAIN-FOCUSED INVENTIONS BY YEAR, JANUARY 2000-JULY 2015 | 193 |
| FIGURE 38 NUMBER OF PAIN MANAGEMENT DEVICES IN DEVELOPMENT, BY GENERAL STATUS | 200 |
| FIGURE 39 PERCENTAGE OF PAIN-FOCUSED CLINICAL TRIALS FOR ALL AGES, BY REGION (%) | 203 |
| FIGURE 40 PERCENTAGE OF PAIN-FOCUSED CLINICAL TRIALS FOR PEDIATRICS, BY REGION (%) | 204 |